| Name | Title | Contact Details |
|---|
Shasta Regional Medical Center is a 226-bed acute care, medical and surgical facility with a full range of ancillary services. We have been serving far Northern California since 1945. Our hospital has a highly efficient and expanded Emergency Department with minimal patient wait times, a technologically advanced cardiac cath lab available 24/7, an accredited Stroke Team and digital (filmless) radiology services. We have more than 600 registered nurses, technicians, and support personnel working alongside more than 300 physicians on staff. Together, our staff is committed to combining the latest proven technology with personal care and attention to help our patients get better.
Zufall Health Center is a Dover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Focus Health is a Kearney, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lenox Hill Hospital, a member of the North Shore-LIJ Health System, is a 652-bed, fully accredited, acute care hospital located on Manhattan’s Upper East Side with a national reputation for outstanding patient care and innovative medical and surgical treatments. US News and World Report has ranked the hospital among the nation’s top 50 in Cardiology and Heart Surgery and among the top 10 hospitals in the state of New York with a total of 11 “high performing” designations for its clinical performance in Cancer, Diabetes and Endocrinology, Ear, Nose and Throat, Gastroenterology and GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology and Neurosurgery, Orthopedics, Pulmonology and Urology.
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.